Evaluation of intra-tympanic dexamethasone in meniere disease

Evaluation of intra-tympanic dexamethasone with alterations of electrocochleography in meniere's patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014050112691N2

Enrollment

Registered

2014-12-08

Start date

2013-02-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere disease. Ménière disease

Interventions

4 mg intratympanic dexamethasone injection 3 doses toally with 1 week interval..

Treatment - Drugs

4 mg intratympanic dexamethasone injection 3 doses toally with 1 week interval.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Definite meniere ; Age beyond 18 years; NOresponse to medical mangment Exclusion criteria: Musculoskeletal disease ; Spinal cord disease; Middle ear disease ; Addiction ;Usage of ototoxic drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vertigo. Timepoint: 1 ; 3 and 6 months. Method of measurement: In respect to standardized questionarie.	—

Secondary

Measure	Time frame
Tinitus ;hearing level. Timepoint: 1 ; 3 and 6 months. Method of measurement: Audiometry / respect to questionarie.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Gharibi

Amir Alam hospital

hessam.gharibi@ymail.com+212 166760245

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026